darunavir has been researched along with zithromax in 6 studies
Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (zithromax) | Trials (zithromax) | Recent Studies (post-2010) (zithromax) |
---|---|---|---|---|---|
1,148 | 224 | 780 | 6,964 | 1,263 | 3,790 |
Protein | Taxonomy | darunavir (IC50) | zithromax (IC50) |
---|---|---|---|
30S ribosomal protein S6 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S7 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L15 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L10 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L11 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L7/L12 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L19 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L1 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L20 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L27 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L28 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L29 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L31 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L31 type B | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L32 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L33 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L34 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L35 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L36 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S10 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S11 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S12 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S13 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S16 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S18 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S19 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S20 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S2 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S3 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S4 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S5 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S8 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S9 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L13 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L14 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L16 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L23 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S15 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L17 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L21 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L30 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L6 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S14 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S17 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S1 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L18 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L2 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L3 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L24 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L4 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L22 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L5 | Escherichia coli K-12 | 0.3 | |
30S ribosomal protein S21 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L25 | Escherichia coli K-12 | 0.3 | |
50S ribosomal protein L36 2 | Escherichia coli K-12 | 0.3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 5 (83.33) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Anselmi, E; Cavanna, L; Citterio, C; Codeluppi, M; Stroppa, EM; Toscani, I; Zaffignani, E | 1 |
Cipriani, MS; Massabeti, R; Valenti, I | 1 |
Danzi, GB; Di Tano, G; Gherbesi, E; Loffi, M; Moschini, L; Regazzoni, V | 1 |
Andena, AM; Cattadori, E; Cavanna, L; Citterio, C; Codeluppi, M; Cremona, G; Gubbelini, M; Maniscalco, P; Muroni, L; Muroni, M; Nolli, M; Nunzio, CD; Pedrazzini, G; Schiavo, R | 1 |
1 review(s) available for darunavir and zithromax
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for darunavir and zithromax
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Methylprednisolone; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infections; COVID-19; Darunavir; Disease Progression; Enoxaparin; Humans; Hydroxychloroquine; Male; Middle Aged; Noninvasive Ventilation; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; Ritonavir | 2020 |
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Darunavir; Electrocardiography; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Male; Middle Aged; Ritonavir; SARS-CoV-2 | 2021 |
COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cobicistat; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Darunavir; Disease Outbreaks; Drug Combinations; Female; Home Care Services; Hospitalization; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Telemedicine; Young Adult | 2021 |